View in EDS

Efficacy, Tolerability, and Pharmacokinetics of Combined Targeted MEK and Dual mTORC1/2 Inhibition in a Preclinical Model of Mucosal Melanoma.

Saved in:
Bibliographic Details
Title: Efficacy, Tolerability, and Pharmacokinetics of Combined Targeted MEK and Dual mTORC1/2 Inhibition in a Preclinical Model of Mucosal Melanoma.
Authors: Wei BR; Laboratory of Cancer Biology and Genetics, Center for Cancer Research, National Cancer Institute, Bethesda, Maryland.; Leidos Biomedical Research, Inc., Frederick, Maryland., Hoover SB; Laboratory of Cancer Biology and Genetics, Center for Cancer Research, National Cancer Institute, Bethesda, Maryland., Peer CJ; Clinical Pharmacology Program and the Genitourinary Malignancies Branch, Center for Cancer Research, National Cancer Institute, Bethesda, Maryland., Dwyer JE; Laboratory of Cancer Biology and Genetics, Center for Cancer Research, National Cancer Institute, Bethesda, Maryland., Adissu HA; Laboratory of Cancer Biology and Genetics, Center for Cancer Research, National Cancer Institute, Bethesda, Maryland., Shankarappa P; Clinical Pharmacology Program and the Genitourinary Malignancies Branch, Center for Cancer Research, National Cancer Institute, Bethesda, Maryland., Yang H; Laboratory of Cancer Biology and Genetics, Center for Cancer Research, National Cancer Institute, Bethesda, Maryland., Lee M; Laboratory of Cancer Biology and Genetics, Center for Cancer Research, National Cancer Institute, Bethesda, Maryland., Peat TJ; Laboratory of Cancer Biology and Genetics, Center for Cancer Research, National Cancer Institute, Bethesda, Maryland., Figg WD; Clinical Pharmacology Program and the Genitourinary Malignancies Branch, Center for Cancer Research, National Cancer Institute, Bethesda, Maryland., Simpson RM; Laboratory of Cancer Biology and Genetics, Center for Cancer Research, National Cancer Institute, Bethesda, Maryland. ms43b@nih.gov.
Source: Molecular cancer therapeutics [Mol Cancer Ther] 2020 Nov; Vol. 19 (11), pp. 2308-2318. Date of Electronic Publication: 2020 Sep 17.
Publication Type: Journal Article; Research Support, N.I.H., Intramural
Journal Info: Publisher: American Association for Cancer Research, Inc Country of Publication: United States NLM ID: 101132535 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1538-8514 (Electronic) Linking ISSN: 15357163 NLM ISO Abbreviation: Mol Cancer Ther Subsets: MEDLINE
Database: MEDLINE Ultimate
FullText Text:
  Availability: 0
Header DbId: mdl
DbLabel: MEDLINE Ultimate
An: 32943547
AccessLevel: 2
PubType: Academic Journal
PubTypeId: academicJournal
PreciseRelevancyScore: 0
IllustrationInfo
Items – Name: Title
  Label: Title
  Group: Ti
  Data: Efficacy, Tolerability, and Pharmacokinetics of Combined Targeted MEK and Dual mTORC1/2 Inhibition in a Preclinical Model of Mucosal Melanoma.
– Name: Author
  Label: Authors
  Group: Au
  Data: <searchLink fieldCode="AU" term="%22Wei+BR%22">Wei BR</searchLink>; Laboratory of Cancer Biology and Genetics, Center for Cancer Research, National Cancer Institute, Bethesda, Maryland.; Leidos Biomedical Research, Inc., Frederick, Maryland.<br /><searchLink fieldCode="AU" term="%22Hoover+SB%22">Hoover SB</searchLink>; Laboratory of Cancer Biology and Genetics, Center for Cancer Research, National Cancer Institute, Bethesda, Maryland.<br /><searchLink fieldCode="AU" term="%22Peer+CJ%22">Peer CJ</searchLink>; Clinical Pharmacology Program and the Genitourinary Malignancies Branch, Center for Cancer Research, National Cancer Institute, Bethesda, Maryland.<br /><searchLink fieldCode="AU" term="%22Dwyer+JE%22">Dwyer JE</searchLink>; Laboratory of Cancer Biology and Genetics, Center for Cancer Research, National Cancer Institute, Bethesda, Maryland.<br /><searchLink fieldCode="AU" term="%22Adissu+HA%22">Adissu HA</searchLink>; Laboratory of Cancer Biology and Genetics, Center for Cancer Research, National Cancer Institute, Bethesda, Maryland.<br /><searchLink fieldCode="AU" term="%22Shankarappa+P%22">Shankarappa P</searchLink>; Clinical Pharmacology Program and the Genitourinary Malignancies Branch, Center for Cancer Research, National Cancer Institute, Bethesda, Maryland.<br /><searchLink fieldCode="AU" term="%22Yang+H%22">Yang H</searchLink>; Laboratory of Cancer Biology and Genetics, Center for Cancer Research, National Cancer Institute, Bethesda, Maryland.<br /><searchLink fieldCode="AU" term="%22Lee+M%22">Lee M</searchLink>; Laboratory of Cancer Biology and Genetics, Center for Cancer Research, National Cancer Institute, Bethesda, Maryland.<br /><searchLink fieldCode="AU" term="%22Peat+TJ%22">Peat TJ</searchLink>; Laboratory of Cancer Biology and Genetics, Center for Cancer Research, National Cancer Institute, Bethesda, Maryland.<br /><searchLink fieldCode="AU" term="%22Figg+WD%22">Figg WD</searchLink>; Clinical Pharmacology Program and the Genitourinary Malignancies Branch, Center for Cancer Research, National Cancer Institute, Bethesda, Maryland.<br /><searchLink fieldCode="AU" term="%22Simpson+RM%22">Simpson RM</searchLink>; Laboratory of Cancer Biology and Genetics, Center for Cancer Research, National Cancer Institute, Bethesda, Maryland. ms43b@nih.gov.
– Name: TitleSource
  Label: Source
  Group: Src
  Data: <searchLink fieldCode="JN" term="%22101132535%22">Molecular cancer therapeutics</searchLink> [Mol Cancer Ther] 2020 Nov; Vol. 19 (11), pp. 2308-2318. <i>Date of Electronic Publication: </i>2020 Sep 17.
– Name: TypePub
  Label: Publication Type
  Group: TypPub
  Data: Journal Article; Research Support, N.I.H., Intramural
– Name: TitleSource
  Label: Journal Info
  Group: Src
  Data: <i>Publisher: </i><searchLink fieldCode="PB" term="%22American+Association+for+Cancer+Research%2C+Inc%22">American Association for Cancer Research, Inc </searchLink><i>Country of Publication: </i>United States <i>NLM ID: </i>101132535 <i>Publication Model: </i>Print-Electronic <i>Cited Medium: </i>Internet <i>ISSN: </i>1538-8514 (Electronic) <i>Linking ISSN: </i><searchLink fieldCode="IS" term="%2215357163%22">15357163 </searchLink><i>NLM ISO Abbreviation: </i>Mol Cancer Ther <i>Subsets: </i>MEDLINE
PLink https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=mdl&AN=32943547
RecordInfo BibRecord:
  BibEntity:
    Identifiers:
      – Type: doi
        Value: 10.1158/1535-7163.MCT-19-0858
    Languages:
      – Code: eng
        Text: English
    PhysicalDescription:
      Pagination:
        StartPage: 2308
    Titles:
      – TitleFull: Efficacy, Tolerability, and Pharmacokinetics of Combined Targeted MEK and Dual mTORC1/2 Inhibition in a Preclinical Model of Mucosal Melanoma.
        Type: main
  BibRelationships:
    HasContributorRelationships:
      – PersonEntity:
          Name:
            NameFull: Wei BR
      – PersonEntity:
          Name:
            NameFull: Hoover SB
      – PersonEntity:
          Name:
            NameFull: Peer CJ
      – PersonEntity:
          Name:
            NameFull: Dwyer JE
      – PersonEntity:
          Name:
            NameFull: Adissu HA
      – PersonEntity:
          Name:
            NameFull: Shankarappa P
      – PersonEntity:
          Name:
            NameFull: Yang H
      – PersonEntity:
          Name:
            NameFull: Lee M
      – PersonEntity:
          Name:
            NameFull: Peat TJ
      – PersonEntity:
          Name:
            NameFull: Figg WD
      – PersonEntity:
          Name:
            NameFull: Simpson RM
    IsPartOfRelationships:
      – BibEntity:
          Dates:
            – D: 01
              M: 11
              Text: 2020 Nov
              Type: published
              Y: 2020
          Identifiers:
            – Type: issn-electronic
              Value: 1538-8514
          Numbering:
            – Type: volume
              Value: 19
            – Type: issue
              Value: 11
          Titles:
            – TitleFull: Molecular cancer therapeutics
              Type: main
ResultId 1